AUSTIN, Texas, Feb. 11, 2025 /PRNewswire/ -- Superior HealthPlan ("Superior"), a leading managed care organization in Texas and a company of Centene Corporation (NYSE: CNC), today released its annual community investment report, demonstrating an ongoing commitment to supporting the health of individuals and families across the state. In 2024, Superior worked with 759 community partners, participated in 2,200 events and presentations, and contributed $1.2 million in grants, sponsorships, and employee donations to further Superior's mission of transforming the health of the communities we serve, one person at a time.

"For the past 25 years, Superior HealthPlan has been committed to providing local support to individuals, families and communities across Texas," said Superior HealthPlan President and CEO, Mark Sanders. "I'm proud of our accomplishments in 2024 as we continued to collaborate closely with our partners to support innovative programs to help Texans address critical health challenges."
For example, in 2024, Superior funded programs that target non-medical drivers of health to improve access to personal care items and mental health resources through these initiatives:
To learn more about Superior's investment in Texas communities and other ways the company gives back, visit SuperiorHealthPlan.com/membersfirst.
About Superior HealthPlan
Founded in 1999, Superior HealthPlan is a managed care company that delivers quality health care throughout Texas. Committed to transforming the health of the community, one person at a time, Superior supports active local involvement in all 254 Texas counties with 3,300 employees throughout the state. Superior is a company of Centene Corporation, a leading healthcare enterprise that is committed to helping people live healthier lives. More information on Superior can be found at www.SuperiorHealthPlan.com.

| Last Trade: | US$33.02 |
| Daily Change: | -0.13 -0.39 |
| Daily Volume: | 1,661,322 |
| Market Cap: | US$16.220B |
July 29, 2025 July 25, 2025 April 25, 2025 February 24, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load